PRESS RELEASE
Rebirthel Co., Ltd.

Room 311, Creation Core Kyoto Mikuruma,
448-5 Kajii-cho, Kamigyo-ku, Kyoto 602-0841 Japan
Phone: (81)75-212-3770
Fax: (81)75-212-3780
URL: https://rebirthel.com/en/

Alliance between Noile-Immune Biotech, Inc. and Rebirthel Co., Ltd. on
PRIME allogeneic CAR-T Cell Therapy using Immune Cells induced fromPluripotent Stem Cells

Rebirthel Co., Ltd. (Kamigyo-ku, Kyoto, President: Masunori Kajikawa,hereinafter "Rebirthel") and Noile-Immune Biotech, Inc. (2-12-10 ShibaDaimon, Minato-ku, Tokyo, President: Koji Tamada, hereinafter "NoileImmune") are pleased to announce that we have entered into a contract oncollaborative research and commercialization of next-generation genemodified immune cell therapy combining Rebirthel’s technology for producing
immune cells from pluripotent stem cells*1 and Noile-Immune’s PRIME(Proliferation-inducing and migration- enhancing) technology*2 for adapting
immune cell therapies such as those of CAR-T cells*3 and TCR-T cells to solidcancer.
The technology for regenerating antigen-specific immune cells frompluripotent stem cells, the fundamental technology of Rebirthel, wasdeveloped based on the research results of Prof. Hiroshi Kawamoto, Directorof Institute for Life and Medical Sciences, Kyoto University, who is thefounder and chief technology advisor of Rebirthel. This technology is expected
to offer new immunotherapies in allogeneic setting cell transplantation andto allow the therapeutic application of all immune-related diseases such ascancer.

www.rebirthel.com

PRIME technology, the fundamental technology of Noile-Immune, related tocancer immune cell therapies such as CAR-T cell therapy, was developed byDr. Koji Tamada, the scientific founder and representative director of NoileImmune and professor of Yamaguchi University Graduate School of Medicine.
PRIME technology not only enhances the functions of gene-modified immune
cells by producing cytokines and chemokines, but also improves the ability ofpatient's own immune systems to cope with cancer cells.
Mr. Masunori Kajikawa says, "I am delighted with this collaboration between
Noile-Immune and Rebirthel as it truly embodies the concepts of “an era
when we can overcome cancer” and “pioneering a new era of treating cancer.”
In order to eradicate cancer, it is the requirement to apply two parties’
strategies to various solid cancers. In this collaboration project, we willdevelop a novel, next-generation, and highly universal immune cell therapy
and advance it as a treatment to address unmet medical needs all over theworld.”
Dr. Tamada also says, "I am very pleased to establish an alliance withRebirthel which has innovative allogeneic immune cell technologies. In thisproject, we will combine PRIME technology of Noile-Immune with Rebirthel’stechnology for generating antigen-specific immune cells from pluripotent
stem cells and develop allogeneic gene-modified immune cells. By combiningof these Japan-origin technologies, I hope we will be able to develop highly
universal, next-generation gene-modified immune cells that can exert
therapeutic effects against solid cancers and to create therapies offered tomorecancerpatients.

We

aimto

developstate-of-the-artcancer

immunotherapies.”
Under this alliance, Noile-Immune and Rebirthel will conduct collaborative
research on allogeneic gene-modified immune cell therapy. Both parties havethe right to commercialize the results obtained from this collaborative
research and to receive royalties from each other under the contract. Further
contract terms are not disclosed.

www.rebirthel.com

[Epexegeses]*1 Pluripotent stem cell

A cell with the ability to differentiate into cells of various tissues and organs(pluripotency) and to self-proliferate (self-renewal ability)*2 PRIME technology

A technology to enhance the function of genetically modified immune cells
such as CAR-T cells and to activate the host's own immune cells. NoileImmune has an exclusive right.
*3 CAR-T cellChimeric antigen receptor T cells are T cell transfected with artificial
chimeric antigen receptors that combine single-chain antibodies specific tocell-surface antigens in cancer with molecular signaling regions involved in
activation of T cells.
nRebirthel Co., Ltd.

A bio-venture originating from Kyoto University, which was established byProfessor Hiroshi Kawamoto, Director of Institute for Life and MedicalSciences, Kyoto University, with the vision of "pioneering a new era oftreating cancer." Utilizing multiple own patented technologies, Rebirthel
aims to provide a novel treatment- allogeneic immune cell therapy.
For more information, please visit https://rebirthel.com/.
nNoile-Immune Biotech Inc.,

Established as a university start-up, aims to contribute to the arrival of anera when we can overcome cancer through the next-generation cancer
immunotherapies, centering on PRIME technology.

www.rebirthel.com